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Summary 
 
Chronic kidney disease (CKD) is a common disorder with rising occurrence worldwide. The 
reported data about its prevalence, advocating the severe outcomes as about 13 % of the adult 
(>65 years old) Japanese population [1] struggling with CKD stages 3 to 5 [2].  
The most refined definition of CKD is the decreased kidney function as demonstrated 
by a glomerular filtration rate of less than 60mL/min/1.73m2 and/or urinary albumin: 
creatinine ratio greater than 3 mg/mmol for at least 3 months duration, by The Kidney Disease: 
Improving Global Outcomes (KDIGO) CKD Work Group [3]. In medical practice, CKD stages 
are diagnosed through estimated glomerular filtration rate (eGFR) blood test and urine 
albumin: creatinine ratio [4]. However, kidney damage can be defined by any one of the 
following conditions: a) pathologic kidney abnormalities, b) persistent proteinuria, c) other 
urine abnormalities, eg, renal hematuria, d) imaging abnormalities, e) eGFR <60 mL/min/1.73 
m2 parted by 90 days which is not associated with a transient, reversible condition such as 
volume depletion [4].  
Hyperphosphatemia (HP) is another important marker for the diagnosis of CKD 
severity in the kidney impaired patients. In such patients, elevated phosphate levels can be 
observed in blood and low phosphate concentration in the excretion of urine due to the kidney 
dysfunctionality. However, the enhanced levels of phosphate are ignored at initial levels of 
CKD, but at advanced stages, this could be the major problem for the toxicity [5]. Generally, 
phosphate binders are prescribed to treat HP at advanced stages, but patients left with severe 
side effects like long exposure of lanthanum carbonate caused lanthanum deposition in bone; 
calcium-based binders are the causative agents of vascular calcifications and heart diseases; 
and iron-based binders are reported for the gastro-intestinal dysfunction as side effects [6]. 
Conditions of HP get worsen by consuming phosphate rich foods, especially processed foods 
which contain Maillard reaction products. 
Since 1970s, Maillard reaction products (MRPs) attracted the researchers for detailed 
investigations. Maillard reaction starts with glycation, a reaction between glucose or its 
autoxidation products with amines, amino acids, peptides, and proteins. Later, reaction 
complexed (sugar derived protein adducts) and cross linked with several compounds to form 
advanced glycation end-products (AGEs) [7]. Elevated levels of hazardous substances like 
reactive carbonyl precursors of AGEs (glyoxal, methylglyoxal) and lipoxidation end products 
such as malonedialdehyde-lysine trigger the renal clearance system activation [8]. AGE 
peptides can be cleared by glomerular filtration with later tubular reabsorption and degradation 
in the kidney and at last, excrete with urine [9]. Healthy human body can clear AGE peptides 
that averages only 0.7 mL/min [10]. Consequences associated with AGEs interactions with 
biologically significant proteins are resulted in the pathogenesis of various diseases like 
diabetes (nephropathy, retinopathy, neuropathy, and atherosclerosis) and in renal failure [11].  
Imbalance in phosphate levels in food is the main cause of CKD either directly (HP) or 
indirectly (MRPs). The phosphate binders are prescribed for the treatment of HP when the 
kidney storage is almost irreversible and dialysis with the restriction of phosphate rich foods 
would worsen the CKD patient’s quality of life. Therefore, in order to prevent CKD, first I 
studied the phosphate driven Maillard reaction and later attempts were made to deliver a safe 
and potential synbiotic formulation: phosphate accumulating organisms (PAOs) which can 
absorb phosphate and Aloe vera which can give stability and strength to PAO under in-vitro 
conditions. Further spray dried powder (Sd) of synbiotic formulation was incorporated into P 
rich food items which can be commercialized not as medication like phosphate binders, but as 
delicious food that can not only prevent HP at early stages and enhance the quality of CKD 
patients’ life but also confer probiotic and prebiotic efficacies. 
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A model of the Maillard system was designed with the use of glucose and ammonium 
sulfate at 1% w/v. Different salts were added to the system, among which HPO42- ion-based 
salts were found to have the stronger accelerating effect on the Maillard reaction. The effect of 
HPO42- ions on the system was studied further by varying the salt concentrations from 1 to 100 
µg/ mL. An inhibitory effect was observed at very low HPO42- ion concentrations (< 50 µg/mL) 
on the Maillard reaction. Then, the approach investigated in this study was applied to a 
fermented and modified Monster energy drink. Similar results were obtained with the drink, 
except for the maximum phosphate concentration which showed inhibitory effect on Maillard 
reaction in the model system. The effective range of phosphate for the inhibition of MRPs 
production was different due to the different system compositions. In the model and fermented 
Monster drink system, the formation of Maillard reaction products can be controlled by 
lowering the HPO42- ion concentration. This is the first report regarding inhibition of Maillard 
reaction products by lowering HPO42- ion concentration and the results could be utilized in 
areas of food chemistry and processing. 
To prevent HP at early stages without degrading the CKD patient’s life by prescribing 
medicines or phosphate binders which confer several harmful health effects. Therefore, I 
evaluated a safer and beneficial probiotic approach to prevent HP that is the capability of lactic 
acid bacteria and bifidobacteria as PAOs for phosphate accumulation. I found that 
Lactobacillus casei JCM 1134 and Bifidobacterium adolescentis JCM 1275 were the best 
PAOs among the tested probiotics [12]. While the current methods of PAOs screening methods 
are still struggling with the lack of systematic analysis of significant parameters affecting 
phosphate accumulation, contamination of glycogen-accumulating organisms, instability of 
pure isolates, sensitivity of screening methods to various parameters and inefficient enrichment 
for relevant metabolic characteristics. Thus, a novel method was developed to overcome these 
issues and isolate elite PAOs. In this approach, PAOs were first enriched in a novel medium 
that promotes phosphate uptake. Subsequently, the cultures were grown in low-pH phosphate-
free media to remove non-PAOs, and further purified by Percoll density gradient 
centrifugation. Finally, elite PAOs were rapidly and efficiently isolated on agar supplemented 
with toluidine blue O, a chromogen that forms a complex with stored phosphate. Finally, elite 
PAOs L. casei JCM 1134 (11th isolate) and B. adolescentis JCM 1275 (8th isolate) were isolated 
based on a semi-quantitative method using agar supplemented with toluidine blue O. 
Importantly, the method is inexpensive, easy, and may be modified for other potential 
microbes. 
However, current methods for estimating microbial phosphate-accumulation capacities 
require significant improvements in terms of specificity and nullifying the interfering agents. 
Therefore, a microbial phosphate estimation method was designed to solve the mentioned 
challenges. The presented method analyzed cell-free broth to assess the phosphate 
accumulation capability of cells. Active cells and the constructed phosphate-deficient cells 
were incubated in assay salt media. After incubation, phosphate-deficient cell-free broth was 
taken as sample and the blank was the active cell-free broth. Therefore, effects of interfering 
agents and other metabolic molecules were avoided and enhanced the specificity remarkably. 
Phosphate contents were assessed by reactions with toluidine blue O. In contrast to the case in 
previous studies, the shift in the first absorbance peak was found to be inversely proportional 
to the phosphate concentration. The minimum detectable phosphate concentrations for the 11th 
isolate of Lactobacillus casei JCM 1134 and 8th isolate of Bifidobacterium adolescentis JCM 
1275 were determined to be 1.24 and 0.4 mg/L, respectively.  
Sd was made using L. casei JCM 1134 and Aloe Vera to prevent HP at early stages of 
development and evaluated its safe delivery and the phosphate accumulating capacity of 
potential probiotics under in-vitro trials. Aloe vera was deacetylated [13] to obtain deacetylated 
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acemannan (DAV) which is insoluble at high pH range and can give stability and strength to 
PAO under in-vitro conditions. Further, DAV was lysine derivatized to lower the zeta potential 
so that phosphate can adsorbed on synbiotic and later adsorbed phosphate would be 
accumulated by PAO. Lysine derivatization of DAV (DAVK) and synbiotic formulation were 
performed simultaneously where 11th isolate of L. casei JCM 1134, DAV, sucrose and lysine 
were mixed in the ratio of 0.7:1:0.012:0.07 respectively and incubated at 37 °C for 3 h. Kinetics 
of DAV adsorption on L. casei and optimization studies were also performed to formulated 
synbiotic preparation. Synbiotic formulation (1% w/v) was spray dried with the supernatant of 
DAV preparation. Subsequently, Sd was evaluated for the phosphate accumulation and 
compared with commercials under in-vitro trials. Synthetic media (phosphate rich), milk and 
coca-cola were subjected to in-vitro experiments with CaCO3, LaCO3, Al(OH)3 and Sd. In-
vitro experiments revealed that Sd showed the comparable result with CaCO3 (the best 
phosphate accumulator among other phosphate binders) in the case of milk and coca-cola while 
due to the safe status of Sd, its application is preferred over CaCO3. However, in the case of 
synthetic media, Sd showed the best phosphate accumulation performance. I observed that the 
capacity of phosphate binder to remove phosphate depends not only on its own chemical 
capacity and chemical & physical environment but also the available form of phosphate. 
Kinetics of phosphate removal with respect to time and phosphate concentration were also 
studied.  
This study delivers the formulation of safe and potential synbiotic preparation as 
phosphate binder and uncovered the diet factor which need to be consider while prescribing 
the best suited phosphate binder as the performance of phosphate binder also depends on its 
affinity for available phosphate form in diet composition. Phosphate binders are medicines and 
are prescribed by medical doctors while Sd can be consumed as diet and fortified with 
phosphate rich foods which may improve the CKD patients’ life as well as prevent HP at early 
stages of development.  
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